Innovation | Ophthalmology Innovation Source

ForSight Reports on Phase II Bimatoprost Ring Results

Phase II results of ForSight Vision5’s bimatoprost ocular ring insert have shown the ring achieves clinically significant reductions in intraocular pressure (IOP) over six months with an acceptable level of safety and tolerability, principal investigator James D. Brandt, MD, reported at OIS@ASCRS. The results were just published online in the journal Ophthalmology. The bimatoprost ring…

Dempsey on Building the Shire Brand in Ophthalmology

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 087″] Robert Dempsey, vice president of ophthalmics at Shire, was charged with building a brand in ophthalmology with no new drugs. Two years later, Shire has – in the words of one physician – one of “the best kept secrets” in eye care. Dempsey explains how Shire came to build something…

New CEO Boorady Explains TearScience’s Strategic Shift

TearScience, the device company focused on the role of the meibomian glands in dry eye, has pivoted its business model to concentrate more on early-stage meibomian gland dysfunction (MGD) with the LipiFlow thermal pulsation device and high-definition imaging of the meibomian glands. Highlights 00:39 – When did you join TearScience and what changes did you…

IBMD Strives for Femto-like Capsulotomies Without the Cost

International Biomedical Devices (IBMD) is in preclinical investigation of its ApertureCTC precision capsulotomy device designed to achieve laser-like precision outcomes in cataract surgery, Chief Medical Officer Mark Packer, MD, reported at OIS@ASCRS 2016. The concept, Dr. Packer said, is to prevent “the heart-stopping capsulorhexis” while overcoming the challenges of “pricey” femtosecond laser-assisted cataract surgery, thus…

Mynosys Eye Commercial Launch of Zepto

Zepto represents an “innovative, disposable capsulotomy device,” said president and CEO John Hendrick. It does not disrupt the natural flow of cataract procedures or patient flow. Its proprietary cutting edge doesn’t burn tissue (no cautery, thermal burning), but instead cleaves the tissue, providing an “unusual edge to the capsulotomy,” he explained. Finally, the device requires…

CEO John Hendrick on Zepto’s Fast Development

Mynosys Cellular Devices is developing Zepto, a disposable device, used in cataract surgery that uses precision pulse technology. The company notes the device is accurate and creates a reproducible capsulotomy that is quick, safe, and affordable. Zepto consists of a silicon suction cup, a nitinol capsulotomy cutting element and an incision finder/push-rod system. Highlights 01:00…

Transcend Medical

From Mythbuster to Dealmaker

Barry Cheskin, CEO, president and co-founder of PowerVision, provides details on his company’s new partnership with Alcon. Video Highlights: 00:30 – Details on Alcon deal including investment and opportunity to acquire. 01:08 – Combination will help bring Fluidvision 2020 to market even sooner. 01:19 – The Power of OIS 01:25 – Were you looking for…

Allotex

The driving force behind Allotex was the observation that the potential interest in synthetic corneal inlay technology was being dampened by the persistent biocompatibility issue. Recognizing the many technological changes that have occurred since Barraquer’s early pioneering epikeratophakia work, the company was established to develop human allograft inlays and onlays to satisfy a growing market…

Five Novel Innovations from WTF@OIS

The “What’s the Future@OIS” session at OIS@ASCRS 2016 showcased five novel innovations in ophthalmology that are difficult to place into any existing categories of ophthalmic devices and drugs. Here’s a quick look at them. Depressurizing goggles for glaucoma. Equinox is developing the Balance Goggles, which create a small vacuum on the eyes for people with…

Device for Profoundly Blind Uses Tongue Electrodes

The profoundly blind form mental images of their surroundings from a variety of stimuli – touch, echo location, the their tip of cane or guide dog – and Wicab Inc. has developed a device that relays visual information via a neuro-stimulating array on the tongue to round out those images. Wicab president and CEO Robert…

Goggles Target Pressure Differentials in Glaucoma

The idea for Equinox, and the first non-surgical, non-drug treatment for glaucoma, came to John Berdahl, MD, while he and his wife were scuba diving. People with high intraocular pressure (IOP) could wear the company’s Balance Goggles overnight to alleviate pressure on and around the optic nerve. Dr. Berdahl, Equinox founder and CEO, reported on…